个人简介
华西医科大学本科、硕士,复旦大学博士;
2009年奥地利维也纳大学博士后,2010-2011年哈佛医学院访问学者。
先后主持由国际组织、自然科学基金、教育部和卫计委委托的四十多项课题研究,作为第一作者或责任作者在国内外学术期刊发表论文100余篇,论著1本译著1本参编5本论著。参与撰写中国药物经济学评价指南;担任value in health, Health policy and planning等国际期刊的评审专家。
研究领域
药物经济学和药品政策、
慢性病经济学及老龄化、
卫生经济与卫生改革研究。
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
1. Sun L, Legood R, Sadique Z, dos-Santos-Silva I, Yang L*. Breast cancer screening programme in China: does one size fit all? A cost-effectiveness analysis based on a Markov model. The Lancet, 2018;392(S2). (IF=53.254)
2. Sun L, Sadique Z, dos-Santos-Silva I, Yang L*, Legood R. Cost-effectiveness of breast cancer screening programme for women in rural China. International journal of cancer, 2019;144(10):2586-2604.(IF= 7.36)
3. Sun L, Legood R, Sadique Z, dos-Santos-Silva I, Yang L*. Cost–effectiveness of risk-based breast cancer screening programme, China Bulletin of the World Health Organization 2018;96:568-577.( IF=6.361)
4. Wen lk, Wu JJ, Fen L, Yang L*, Qian F. Comparing the economic burden of ischemic stroke patients with and without atrial fibrillation: a retrospective study in Beijing, China. Current Medical Research and Opinion,2017,33(10): 1789-1794.(IF=2.757)
5. Yang, L., Sun, L., Wen, L. et al. Financing strategies to improve essential public health equalization and its effects in China. Int J Equity Health. (IF=1.738)
6. Yang, L, Liu, Y., Wen, L. et al. Examining the Impact of Rehospitalization on Healthcare Cost of Myocardial Infarction Patients in Beijing: a Retrospective, Observational study .Adv Ther. 2017 Jan;34(1):109-119. (IF= 2.709)
7. Yang L, Tan SC, Chen C, Wang XZ, Li XY and Yang XY. Economic Evaluation of Sevelamer versus Calcium-Based Binders in Treating Hyperphosphatemia among Patients with End-Stage Renal Disease in China. Clinical Therapeutics.2016;38(11):2462-2470.(IF= 2.947)
8. YANG WY, Zhuang YM, Li YK, Wang Q, Bian RW, Shen JG, Hammerby E and Yang L*. Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A 1 chieve observational study. Health and Quality of Life Outcomes 2014, 12:137.(IF=2.12)
9. Yang L, Christensen T, White J, Sun F. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in a chinese setting: a health economic model based on the predictive study. Value in health,2012;15(1s): S56-59. (IF=2.191)
10. Yang L, Li M, Tao LB, et al. Cost Effectiveness of Long-Acting Risperidone Injection versus Alternative Atypical Antipsychotic Agents in Patients with Schizophrenia in China. value in health.2009;12(s3):s66-69. (IF=2.191)
学术兼职
中国卫生经济学会理事、医疗保险专业委员会副主任委员兼秘书长;曾担任发改委药品评价中心咨询专家、卫生部基本药物制度、公立医院改革咨询专家,北京卫计委政策咨询专家。